Company: RGBP
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001641172-25-011206
Chunk: 9

Company: Regen BioPharma Inc
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 9
---
ivable 10,000
Accounts Payable 30,563
Notes Payable 400,000
Accrued Expenses Related Parties 162,011
Notes Payable Related Party -
Accrued Expenses 647,072
Enterprise Value 1,948,562
Less: Total Debt ( 1,239,646
Portion of Enterprise Value Attributable to Shareholders 708,916
Fair Value per Shares 0.0155
The abovementioned constitute the Company’s
sole related party investment securities as of December 31, 2024.

5. ACCRUED EXPENSES

Accrued Expenses were comprised of the following:

SCHEDULE OF ACCRUED EXPENSES

                              As of                                 As of                              
                              December 31, 2024                     September 30, 2024                 
 ───────────────────────────────────────────────────────────────────────────────────────────────────────
  Accrued payroll taxes       $                          4,241      $                           4,241  
  Accrued Interest                                     387,885                                362,533  
  Accrued Payroll                                    1,256,630                              1,256,630  
  Accrued Rent                                          17,500                                      -  
  Other Accrued Expenses                                41,423                                 41,423  
  Total                       $                      1,707,680      $                       1,664,827  

6. UNEARNED INCOME

Unearned income is attributable to payments made to
the Company and its wholly owned subsidiary pursuant to two license agreements for which income is recognized over the terms of the agreement.

7. NOTES PAYABLE

Notes Payable comprise of below:

(a) RELATED PARTY

Notes payable to related parties
consisted of the following:

SCHEDULE
OF NOTES PAYABLE TO RELATED PARTIES

                                              As                         As                     
  David Koos                                  $               1,708      $               1,708  
  BST Partners                                               46,599                          -  
  Zander Therapeutics, Inc.                                  59,200                     40,000  
  Total notes payable to related parties      $             107,507      $              41,708  

$1,708lent to the Company by
David Koos is due and payable at the demand of the holder and bears simple interest at a rate of15% per annum.

$15,000lent to the Company by Zander Therapeutics,
Inc